The 24th China Hi-Tech Fair Opens on November 15 in Shenzhen, China
The 24th China Hi-Tech Fair (CHTF 2022) kicked off in Shenzhen on November 15, 2022. Taking place until November 19, this year’s event has been comprehensively upgraded to the largest ever, integrating new product and technology launches, product and solution exhibitions, trade negotiations, and investment finance, across a diverse variety of hi-tech sectors including biomedicine, new materials, modern agriculture, fine chemicals, aerospace, new energy, high-end equipment manufacturing, energy conservation and environmental protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006208/en/
International Pavilion and IT Exhibition of CHTF 2022 (Photo: Business Wire)
CHTF 2022 will gather a total of 5,000 exhibitors, including domestic multinationals and industry champions such as China General Nuclear Power Corporation, Huawei, ZTE, and Han’s Laser, along with hi-tech “little giants” such as: Kemai, a digital payment system provider; Keanda, a rail transit products manufacturer; and Insighters, a medical technology startup.
Also participating are overseas exhibitors from 38 countries including Brazil, Canada, Finland and Russia, some of which will join via CHTF 2022’s virtual platform. Among them, the Russian Ministry of Education and Technology and the Bavarian State Government of Germany, two of CHTF’s longstanding cooperation partners, have been sending delegations to CHTF for more than 20 consecutive years.
CHTF 2022 will host the inaugural Water Conservation and Innovation Exhibition, which together with a high-tech talent attraction show and an expo for emergency safety will boost the appeal of the event.
Meanwhile, the CHTF Hi-Tech Forum will be held on November 15-17, with a key focus on the digital economy, metaverse, quantum computing, AI, cloud computing, “lighthouse” factories and smart cities, future mobility, and “dual-carbon” goals. The forum will be livestreamed here.
The X-Lake Forum 2022, as the main side-forum of CHTF 2022, was held on November 15. Focused on “openness, integration and future”, this forum discussed development trends and shared cutting-edge hi-tech innovations. John Lee, Chief Executive of the Hong Kong Special Administrative Region; Ho Iat-seng, Chief Executive of the Macao Special Administrative Region; and Ciyong Zou, Director at UNIDO delivered video speeches. Scholars, academicians and renowned industry leaders including Nobel Laureate Roger D. Kornberg delivered keynote speeches at the forum.
More information is available on https://www.chtf.com/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006208/en/
Contact information
For exhibitor and visitor
Ms. XIE Yan, +8675582848652, selenaxie@chtf.com
Ms. WANG Peggie, +8675582848962, wangyq@chtf.com
Ms. CUI Can, +8675582848764, cathy_cui@chtf.com
Ms. YANG Dan, 86 755 8284 8695, yangd@chtf.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 14:57:00 EET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 14:30:00 EET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness15.1.2026 14:01:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation. As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories. The collaboration, first announced on June 3, 2025, included the following key financial terms: Upfront Consideration: $75 million cash payment to Agenus for transfer of biologics manufac
WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion15.1.2026 14:00:00 EET | Press release
WHOOP, the human performance company, announces a landmark creative partnership with acclaimed designer Samuel Ross MBE, who joins as Global Creative Director, WHOOP x SR_A to lead a multiyear collaboration between the two brands titled PROJECT TERRAIN. The collaboration signals the ongoing evolution of WHOOP from a pioneering wearable technology company into a brand shaping not just the future of personal health but also its intersection with performance fashion and cultural design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115643104/en/ WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion As the first performance design collaboration for WHOOP, the partnership represents a new chapter for the brand. Under Ross’ direction, PROJECT TERRAIN will deliver a bespoke capsule collection including limited-edition, customized WHOOP bands. The range will also
TNG Digital and EPOS Launch EPOS360 and EPOS360 BlueTap in Malaysia to Help Local SMEs Grow with AI and Unique Payment Capabilities15.1.2026 12:23:00 EET | Press release
TNG Digital Sdn. Bhd. (“TNG Digital”), the operator of Malaysia’s leading digital financial services and lifestyle app, TNG eWallet, and EPOS, the all-in-one SME transformation platform of Ant International, have jointly announced the launch of EPOS360 in Malaysia, with a suite of AI-powered growth tools and unique payment capabilities to support the digitalisation of Malaysian businesses, particularly SMEs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115763131/en/ [From left] Mr. Sarveswaran Raja Gopal, Chief Commercial Officer of TNG Digital; Mr. Alan Ni, Chief Executive Officer of TNG Digital; [middle] En. Anuar Fariz Fadzil, Chief Executive Officer of Malaysia Digital Economy Corporation (MDEC); Mr. Gary Liu, Chief Executive Officer of Antom and Senior Vice President of Ant International; and Mr. Alan Wang, Chief Executive Officer of EPOS and Vice President of Ant International, at the launch of EPOS360 and EPOS360
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom